OncoSec signs collaborative research agreement for Tavoplus in breast cancer
OncoSec have entered into a collaborative research agreement to evaluate the use of OncoSec's proprietary Tavoplus enhanced IL-12 DNA-plasmid in combination or sequence with a HER2-plasmid vaccine administered with OncoSec's intratumoral delivery system. OncoSec will provide its proprietary Tavo and its new electroporation generator, Apollo, using lower voltage and a longer pulse width which greatly increased DNA-plasmid cellular transfection rates, to Duke University's Center for Applied Therapeutics. Duke University investigators will conduct preclinical studies using plasmid vaccines targeting HER2 in combination with plasmid vaccines and TAVO in a newly developed endogenous mouse model of HER2+ breast cancer. Additionally, Duke investigators will use Tavo with their high-intensity ultrasound tumor ablation models to explore the impact of IL-12 delivery on the development of systemic immunity.